ABSTRACT
OBJECTIVES: The number of bariatric procedures has significantly increased in Brazil, especially in the public Unified Health System. The present study describes health outcomes and medication use in obese patients treated in a major hospital that performs publicly funded surgery in Brazil. METHODS: A retrospective, single center study was conducted to collect real-world evidence of health outcomes and medication use in 247 obese patients (female, 82.2%) who underwent open Roux-en-Y gastric bypass. Changes in weight and body mass index (BMI), presence of apnea, hypertension, and type 2 diabetes (T2D), and medication use (hypertension, diabetes, and dyslipidemia) were assessed preoperatively and up to 24 months postoperatively. The mean cost of medications was calculated for the 12-month preoperative and 24-month postoperative periods. RESULTS: During the surgery, the mean age of patients was 43.42 years (standard deviation [SD], 10.9 years), and mean BMI was 46.7 kg/m2 (SD, 6.7 kg/m2). At 24 months, significant declines were noted in weight (mean, -37.6 kg), BMI (mean, -14.3 kg/m2); presence of T2D, hypertension, and apnea (-29.6%, -50.6%, and -20.9%, respectively); and number of patients using medications (-66.67% for diabetes, -41.86% for hypertension, and -55.26% for dyslipidemia). The mean cost of medications (total costs for all medications) decreased by >50% in 12-24 postoperative months compared to that in 12 preoperative months. CONCLUSION: Roux-en-Y gastric bypass successfully reduced weight, BMI, and comorbidities and medication use and cost at 24 months in Brazilian patients treated in the public Unified Health System.
Subject(s)
Humans , Female , Adult , Drug Prescriptions/statistics & numerical data , Obesity, Morbid/surgery , Gastric Bypass/methods , Laparoscopy , Bariatric Surgery , Obesity, Morbid/complications , Brazil , Weight Loss , Gastroesophageal Reflux/complications , Gastroesophageal Reflux/drug therapy , Body Mass Index , Retrospective Studies , Treatment Outcome , Outcome Assessment, Health Care , Diabetes Complications/drug therapy , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Dyslipidemias/complications , Dyslipidemias/drug therapy , Hypertension/complications , Hypertension/drug therapyABSTRACT
O Querubismo é uma doença óssea rara, não neoplasica, de caráter hereditário, que acomete crianças com predileção pelo gênero masculino cujas características clínicas são aumento da mandíbula e maxila de maneira bilateral e indolor, que tende a progredir até a puberdade, quando acontece o processo de remissão espontânea. O tratamento para a doença depende do curso clínico, porém não existe nenhum protocolo definindo qual é o melhor tipo de tratamento para cada caso. Sendo assim, fica a critério do cirurgião-dentista avaliar o melhor procedimento para seu paciente